VYEPTI
VYEPTI (Eptinezumab-jjmr) is an FDA-approved monoclonal antibody infusion therapy indicated for the prevention of migraine in adult patients. Each single-dose, preservative-free 1×1 EA vial contains Eptinezumab-jjmr, formulated for intravenous administration under professional supervision.
Eptinezumab works by blocking the calcitonin gene-related peptide (CGRP) ligand, a key mediator in migraine pathophysiology. By inhibiting CGRP, VYEPTI helps reduce the frequency, severity, and duration of migraine attacks, providing patients with a targeted preventive therapy for chronic or recurrent migraines.
InfusionMed USA, based in Carrollton, Texas, supplies VYEPTI and other specialty neurology infusion therapies to hospitals, clinics, and specialty infusion centers across Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain compliance, proper handling, and timely delivery for licensed healthcare providers.
For professional use only.
Download Form